Anaphylaxis and cardiovascular disease: therapeutic dilemmas

Clinical and Experimental Allergy

Volumn 45, Issue 8, 2015, Pages 1288-1295

  Lieberman, P ^a   Simons, F E R ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID;

ACUTE CORONARY SYNDROME; ANAPHYLAXIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG SAFETY; EVIDENCE BASED PRACTICE; HIGH RISK PATIENT; HUMAN; KOUNIS SYNDROME; MEDLINE; PRIORITY JOURNAL; REVIEW; SURGICAL PATIENT; TREATMENT INDICATION; ANIMAL; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; COMPLICATION; HEART CONTRACTION; IMMUNOLOGY; MAST CELL; PATHOLOGY;

ANAPHYLAXIS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MAST CELLS; MYOCARDIAL CONTRACTION; MYOCARDIUM;

EID: 84937434796     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12520     Document Type: Review

References (54)

1. Sampson HA, Muñoz-Furlong A, Campbell RL et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391-7.
2. Simons FER, Ardusso LR, Bilò MB et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587-93.e1-22.
3. Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Aust 2006; 185:283-9.
4. Soar J, Pumphrey R, Cant A et al. Emergency treatment of anaphylactic reactions-guidelines for healthcare providers. Resuscitation 2008; 77:157-69.
5. Lieberman P, Nicklas RA, Oppenheimer J et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477-80.
6. Muraro A, Roberts G, Worm M et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014; 69:1026-45.
7. Worm M, Edenharter G, Ruëff F et al. Symptom profile and risk factors of anaphylaxis in Central Europe. Allergy 2012; 67:691-8.
8. Momeni M, Brui B, Baele P, Matta A. Anaphylactic shock in a beta-blocked child: usefulness of isoproterenol. Pediatr Anesth 2007; 17:897-9.
9. Cunnington C, McDonald JE, Singh RK. Epinephrine-induced myocardial infarction in severe anaphylaxis: is nonselective β-blockade a contributory factor? Am J Emerg Med 2013; 31:759.
10. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606-10.
11. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130:698-704.
12. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clin Exp Allergy 2014; 44:747-55.
13. Lee S, Hess EP, Nestler DM et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013; 131:1103-8.
14. Ruëff F, Przybilla B, Biló MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-54.
15. Ruëff F, Vos B, Oude Elberink J et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014; 44:736-46.
16. Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171.
17. TenBrook JA Jr, Wolf MP, Hoffman SN et al. Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol 2004; 113:977-82.
18. Gangemi S, Spagnolo EV, Cardia G, Minciullo PL. Fatal anaphylactic shock due to a dental impression material. Int J Prosthodont 2009; 22:33-4.
19. Marone G, Bova M, Detoraki A, Onorati AM, Rossi FW, Spadaro G. The human heart as a shock organ in anaphylaxis. Novartis Found Symp 2004; 257:133-49.
20. Triggiani M, Montagni M, Parente R, Ridolo E. Anaphylaxis and cardiovascular diseases: a dangerous liaison. Curr Opin Allergy Clin Immunol 2014; 14:309-15.
21. Chávez-Sánchez L, Espinosa-Luna JE, Chávez-Rueda K, Legorreta-Haquet MV, Montoya-Díaz E, Blanco-Favela F. Innate immune system cells in atherosclerosis. Arch Med Res 2014; 45:1-14.
22. Palmiere C, Comment L, Vilarino R, Mangin P, Bonetti LR. Measurement of beta-trypase in post-mortem serum in cardiac deaths. J Forensic Leg Med 2014; 23:12-8.
23. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 2010; 113:301-9.
24. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123:434-42.
25. Campbell RL, Hagan JB, Li JT et al. Anaphylaxis in emergency department patients 50 or 65 years or older. Ann Allergy Asthma Immunol 2011; 106:401-6.
26. Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252-7.
27. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008; 106:392-403.
28. Pfister CW, Plice SG. Acute myocardial infarction during a prolonged allergic reaction to penicillin. Am Heart J 1950; 40:945-7.
29. Kounis NG, Zavras GM. Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 1991; 45:121-8.
30. Taggar JS, Watson T, Musarrat K, Millane T. Kounis syndrome presenting as ST-segment elevation myocardial infarction following a hymenoptera (bee) sting. Int J Cardiol 2009; 136:e29-30.
31. Biteker M, Duran NE, Biteker FS et al. Allergic myocardial infarction in childhood: Kounis syndrome. Eur J Pediatr 2010; 169:27-9.
32. Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 2006; 110:7-14.
33. Kounis NG, Mazarakis A, Tsigkas G, Giannopoulos S, Goudevenos J. Kounis syndrome: a new twist on an old disease. Future Cardiol 2011; 7:805-24.
34. Kounis NG. Coronary hypersensitivity disorder: the Kounis syndrome. Clin Ther 2013; 35:563-71.
35. Ridella M, Bagdure S, Nugent K, Cevik C. Kounis syndrome following beta-lactam antibiotic use: review of literature. Inflamm Allergy Drug Targets 2009; 8:11-6.
36. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eight Joint National Committee (JNC 8). JAMA 2014; 311:507-20.
37. Ryan TJ, Anderson JL, Antman EM et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28:1328-428.
38. Nassiri M, Babina M, Dolle S, Edenharter G, Rueff F, Worm M. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2014 (in press); http://dx.doi.org/10.1016/j.jaci.2014.09.004.
39. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's: the pharmacological basis of therapeutics, 12th edn. New York: McGraw-Hill Companies, Inc. 2011:277-334.
40. Simons KJ, Simons FER. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354-61.
41. Sheikh A, Shehata YA, Brown SGA, Simons FER. Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy 2009; 64:204-12.
42. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol 2003; 3:313-8.
43. Vadas P, Perelman B. Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cells. J Allergy Clin Immunol 2012; 129:1329-33.
44. Campbell RL, Bellolio MF, Knutson BD et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract 2015; 3:76-80.
45. Field JM, Hazinski MF, Sayre MR et al. Part 1: Executive summary: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010; 122:S640-56.
46. Khoueiry G, Abi Rafeh N, Azab B et al. Reverse Takotsubo cardiomyopathy in the setting of anaphylaxis treated with high-dose intravenous epinephrine. J Emerg Med 2013; 44:96-9.
47. Kanwar M, Irvin CB, Frank JJ, Weber K, Rosman H. Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution. Ann Emerg Med 2010; 55:341-4.
48. Wheeler DW, Carter JJ, Murray LJ et al. The effect of drug concentration expression on epinephrine dosing errors: a randomized trial. Ann Intern Med 2008; 148:11-4.
49. Gaeta TJ, Clark S, Pelletier AJ, Camargo CA. National study of US emergency department visits for acute allergic reactions, 1993 to 2004. Ann Allergy Asthma Immunol 2007; 98:360-5.
50. Grabenhenrich L, Hompes S, Gough H et al. Implementation of anaphylaxis management guidelines: a register-based study. PLoS One 2012; 7:e35778.
51. Manivannan V, Hess EP, Bellamkonda VR et al. A multifaceted intervention for patients with anaphylaxis increases epinephrine use in adult emergency departments. J Allergy Clin Immunol Pract 2014; 2:294-9.
52. 1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62:830-7.
53. 2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review. Ann Allergy Asthma Immunol 2014; 112:126-31.
54. Choo KJ, Simons FER, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev 2012; 4:CD007596.